儿童青少年重症哮喘急性发作皮下肾上腺素辅助治疗的系统评价
该系统评价评估在短效β2受体激动剂和全身糖皮质激素标准一线治疗基础上加用皮下肾上腺素,对儿童青少年重症哮喘急性发作的疗效。结果显示,与单用标准一线治疗相比,加用皮下肾上腺素未改善哮喘症状,也未改善肺功能检查结果。
要点
- 加用皮下肾上腺素未改善儿童重症哮喘急性发作的症状。
- 加用皮下肾上腺素未改善肺功能检查结果。
- 多数国际指南不推荐常规使用皮下肾上腺素,除非合并过敏反应或血管性水肿。
核心结论
- 在标准一线治疗基础上加用皮下肾上腺素,未能改善儿童青少年急性重症哮喘发作的症状或肺功能。
研究设计与样本
- 该研究为WHO委托开展的系统评价,纳入随机对照试验,对象为急性重症哮喘发作的儿童和青少年。
主要发现
- 与单用标准一线治疗相比,加用皮下肾上腺素未改善哮喘症状。
- 与单用标准一线治疗相比,加用皮下肾上腺素未改善肺功能检查结果。
临床怎么用
- 现有证据不支持在标准一线治疗基础上常规加用皮下肾上腺素治疗儿童重症哮喘急性发作。
局限性
- 需要进一步开展设计良好的随机对照试验,以评估皮下肾上腺素在儿童急性哮喘管理中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
WHAT IS ALREADY KNOWN ON THIS TOPIC Many international guidelines discourage the use of subcutaneous epinephrine in acute asthma exacerbation unless it is part of an anaphylactic reaction or angio-oedema. It may be used occasionally for life-threatening asthma alongside the standard first-line treatment. WHAT THIS STUDY ADDS Compared with standard first-line treatment alone: Adding subcutenaous epinephrine does not improve asthma symptoms Adding subcutaenous epinephrine does not improve lung function tests. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY Further well-designed randomised controlled trials are needed to further evaluate the role of subcutaneous epinephrine in managing acute asthma in children. Introduction This is one of a series of systematic reviews commissioned by WHO to inform consolidated recommendations for managing common childhood illnesses. The recommendations will update the existing guidance in the Pocket Book of Hospital Care...
引用
- Archives of Disease in Childhood:Use of subcutaneous epinephrine in addition to standard first-line treatment with short-acting {beta}2-agonist and systemic steroids in children and adolescents with an acute severe asthma exacerbation: a systematic review of randomised controlled trials
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。